Three months after earning an approval to treat chronic heart failure with their SGLT2 inhibitor Jardiance, Eli Lilly and Boehringer Ingelheim have posted new data …
Chasing rivals from AstraZeneca and Eli Lilly/Boehringer Ingelheim, Johnson & Johnson’s Invokana is vying for a piece of the lucrative heart failure market. J&J’s Type …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
